Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED.WS | N.MMED | N.MMED.WA | N.MMED.WR

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Bullboard Posts
Comment by grumpymonkey007on Nov 28, 2011 6:57pm
161 Views
Post# 19272660

RE: RE: RE: RE: RE: This stock sucks

RE: RE: RE: RE: RE: This stock sucksTerry, BRD has around 40MM in debt from memory, has done a couple of flow-through share offerings and hedge 12% of our production to a third party.

But to what I was saying about people possibly inferring that the board could be rewarding failure -

- August of 2011 alone Brigus granted at least 2,500,000 options according to canadianinsider.

FAILED: - 27 Sep 2010 News Release. Brigus target steady state production for underground in Q2 2011

FAILED:- 15 Nov 2010. Brigus target for 2011 production is 102-112Koz

LIKELY FAILURE:- 15 Nov 2010. Brigus plans for Goldfields Project to become a producing mine in 2013. The decision has been postponed until Black fox is under control.

FAILED:- 31 March 2011 MD&A. Brigus communicate Q2/3/4 production target of 71-75Koz

FAILED:- 31 March 2011 MD&A. Q2/3/4 cost per Oz $500-550.  Actual cost still >$800 at Q3

FAILED:- 31 March 2011 MD&A. 2011 Production target 80-80Koz.

FAILED:- 7 June 2011 Mine update. Q2 production target 16.5-18Koz.  Actual production was 15.6Koz which was only 87% of 2010 Q2 production

FAILED:- 7 June 2011 Mine update. Q3 production target 26Koz.

FAILED:- 7 June 2011 Mine update.  2011 production target 73- 80Koz

FAILED:- 7 June 2011 Mine update.  Cast cost per oz $575 to $625. Actual cost still >$800 at Q3

FAILED:- 14 June 2011 Q1 results. Company reiterated 2011 production 73-80Koz

FAIELD:- 14 June 2011 Q1 results. Company reiterated cost of $575-625 per oz.

FAILED:- 14 June 2011 Q1 results. Company reiterated Q2 production at 16.5-18Koz.  Actual 15.7Koz

FAILED:- 14 June 2011 Q1 results. Company reiterated 26Koz by Q3. Actual 16.8Koz in Q3

FAILED:- 15 Aug 2011 Q2 results. Q3 production estimate 17.5Koz. Actual 16.8Koz in Q3

FAILED:- 15 Aug 2011 Q2 results. Q4 production estimate 19.5Koz. Subsequently revised down 14 Nov

Cheers,

GM

Bullboard Posts